TRIAGE. SORT. PRIORITIZE.

 

cmTriage™ from CureMetrix is the first FDA-cleared software in the U.S. intended to provide a notification triage code to the radiologist’s mammography worklist based on the presence of a suspicious region of interest found by the underlying algorithm. This workflow optimization tool enables a radiologist to customize their 2D mammogram or mammography worklist based on cases that may need immediate attention.

With cmTriage, a radiologist can sort and prioritize cases in their worklist based on the presence of suspicious regions of interest found by the underlying algorithm. This gives the radiologist the opportunity to tackle the more difficult mammograms with a heightened awareness, or perhaps to assign those cases to the specialist best suited to interpret them.

cmTriage can also be used to optimize clinical protocol and maximize a clinic’s utilization of resources. cmTriage takes less than five minutes to process a study, so it seamlessly integrates into a radiologist’s workflow. Additionally, cmTriage is cloud-based so there are no added systems to install or buttons to click. The software is both DICOM and HIPAA compliant and no PHI ever leaves the hospital.

cmTriage

  • Works across all breast densities.

  • Works with both mass and calcifications.

  • According to the Breast Cancer Surveillance Consortium (BCSC), the average sensitivity of a radiologist is 84.4% and on average they are recalling 9.6% of cases. cmTriage only flags 8.2% of cases at the same sensitivity.1

  • At the increased default sensitivity of 93%, cmTriage will still only identify 24% of your worklist as suspicious while also potentially catching 1 to 2 more cancers per 1,000 screening cases.
     

FDA Cleared

cmTriage is FDA cleared as a notification-only, parallel workflow tool used to identify specific patients to a radiologist based on the presence of at least one suspicious finding to support standard of care image interpretation. It is easy to implement clinically and enables a radiologist to prioritize the most suspicious cases and optimize their workflow.

______________________________________________________________________________

  1. NCI-funded Breast Cancer Surveillance Consortium (HHSN261201100031C). Downloaded 9/5/2018 from the Breast Cancer Surveillance Consortium Web site –http://breastscreening.cancer.gov/statistics/benchmarks/diagnostic/2009/tableSensSpec.html

  2. FDA 510(k) Submission # / S# physician labeling.

US: +1.443.531.6700

UAE: +971.4.288.8137

Value@AllianceCareTech.com

  • White LinkedIn Icon
  • White Twitter Icon
  • White Facebook Icon
  • White YouTube Icon

© 2020 by Alliance Care Technologies